Ordering
Available Variants5 mg
CHA.59277-5mg
Price
€102.40
Available – Dispatch in 14 days
25 mg
CHA.59277-25mg
Price
€417.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.59277-5mg | €102.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.59277-25mg | €417.60 |
≥98% (HPLC), pan-retinoic acid receptor (RAR) antagonist, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C28H24O2 |
|---|---|
| CAS Number | 171746-21-7 |
| Molecular Weight | 392.49 |
| NACRES | NA.77 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD00943817 |
| Assay | ≥98% (HPLC) |
| Form | powder |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
AGN 193109, also known by its CAS number 171746-21-7, is a potent and selective inhibitor of the enzyme acetylcholinesterase. This compound has been extensively studied for its potential therapeutic applications, particularly in the treatment of neurological disorders such as Alzheimers disease. By inhibiting the breakdown of acetylcholine, AGN 193109 increases the concentration of this neurotransmitter in the brain, thereby enhancing cholinergic transmission. The compounds high selectivity and potency make it an attractive candidate for further research and development. Additionally, AGN 193109 has been shown to exhibit a favorable pharmacokinetic profile, with good oral bioavailability and a suitable half-life, making it a promising lead compound for the development of novel treatments for various neurological conditions. Further studies are needed to fully explore its therapeutic potential.
